Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update
| العنوان: | Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update |
|---|---|
| المؤلفون: | Therese W. Fabricius, Birger Thorsteinsson, Ulrik Pedersen-Bjergaard |
| المصدر: | Expert Opinion on Pharmacotherapy. 22:2251-2259 |
| بيانات النشر: | Informa UK Limited, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Blood Glucose, Insulin degludec, medicine.medical_specialty, medicine.medical_treatment, Insulin Glargine, NPH insulin, Hypoglycemia, law.invention, Randomized controlled trial, law, Internal medicine, medicine, Humans, Hypoglycemic Agents, Insulin, Pharmacology (medical), Insulin detemir, Glycated Hemoglobin, Pharmacology, Type 1 diabetes, business.industry, Insulin glargine, General Medicine, medicine.disease, Insulin, Long-Acting, Diabetes Mellitus, Type 1, Endocrinology, Diabetes Mellitus, Type 2, business, medicine.drug |
| الوصف: | Introduction Type 1 diabetes is characterized by insulin deficiency and requires near-physiological insulin replacement. In most patients, this is accomplished by basal bolus therapy consisting of a long-acting basal insulin administered once or twice daily and short-acting insulin with main meals. Several long-acting insulin analogs have been developed to optimize basal insulin therapy. Areas covered This paper reviews the design of - and data from - randomized controlled trials (RCTs) to assess glucose lowering efficacy and safety of long-acting insulin analogs for the treatment of type 1 diabetes. Expert opinion Due to the non-inferiority treat-to-target design of insulin, RCTs treatment differences primarily appear as differences in hypoglycemia risk. Data suggest that the first generation long-acting insulin analogs insulin glargine U100 and insulin detemir have a similar glucose lowering efficacy compared to NPH insulin but a lower risk of hypoglycemia, particularly during nighttime. The newer analogs insulin glargine U300 and insulin degludec provide non-inferior efficacy, although insulin glargine U300 is less potent unit-to-unit. Insulin degludec reduces hypoglycemia risk compared to insulin glargine U100. Future studies should explore the potential for further improvement of treatment results in type 1 diabetes by a structured approach to personalization of basal insulin therapy. |
| تدمد: | 1744-7666 1465-6566 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3f12ead6ff2c3d0c7965835ccf49889Test https://doi.org/10.1080/14656566.2021.1970136Test |
| رقم الانضمام: | edsair.doi.dedup.....e3f12ead6ff2c3d0c7965835ccf49889 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17447666 14656566 |
|---|